Loading patent…
AssigneeGencurix Inc.
InventorsYoung Kee SHIN, Young-Deug Kim, En Sel Oh, Jun Young Choi, Sang Rea Cho
Estimating the term…
A gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof is disclosed, and more specifically a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3 member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.
A method for predicting a prognosis of breast cancer, comprising:
A composition for predicting or diagnosing a prognosis of breast cancer, the composition comprising a primer pair as an active ingredient, wherein the primer pair is for at least one gene selected from the group consisting of TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2), and HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1), and wherein the primer pair is selected to amplify a target gene through PCR amplification.
A method for calculating a predictive value of a prognosis of breast cancer to provide information necessary for predicting or diagnosing a prognosis of a breast cancer patient, the method comprising:
A method for predicting or diagnosing a prognosis of breast cancer, the method comprising using a primer pair to measure a mRNA expression level of a selected gene from a sample of a breast cancer patient, wherein the primer pair is for at least one gene selected from the group consisting of TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2), and HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1), and wherein the primer pair is selected to amplify a target gene through PCR amplification.
A primer pair for at least one gene selected from the group consisting of TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2), and HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1), wherein the primer pair is selected to amplify a target gene through PCR amplification.
Use of a primer pair for preparing an agent for predicting a prognosis of breast cancer, wherein the primer pair is for at least one gene selected from the group consisting of TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2), and HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1), and wherein the primer pair is selected to amplify a target gene through PCR amplification.
A method for calculating a predictive value of a prognosis of breast cancer to provide information necessary for predicting or diagnosing a prognosis of a breast cancer patient, comprising:
Dependencies are inferred from the claim text.